Entry into a Material Definitive Agreement. Committed Equity Facility of up to $50 million On August 12, 2026, ENvue Medical, Inc. (the “Company”) entered into a Common Shares Purchase Agreement (the “Purchase Agreement”), with an institutional investor (the “Investor”), relating to a committed equity facility (the “Facility”). Pursuant to the Purchase Agreement, the Company has the right from time to time at its option to sell to the Investor up to $50.0 million of its shares of common stock…

Director — David Johnson, Nino Pionati: Two directors resigned and were replaced by new appointees.

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On July 10, 2026, ENvue Medical, Inc. (the “Company”) received a letter (the “Staff Determination Letter”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the Staff has determined that the closing bid price of the Company’s common stock, par value $0.001 per share (the “Common Stock”), has been below $1.00 per share…

Chairman of the Board of Directors — David Johnson: Appointment of David Johnson as Chairman of the Board of Directors.

Material Modification to Rights of Security Holders. The matters described in

Entry into a Material Definitive Agreement. As previously disclosed in the Current Report on Form 8-K filed on July 22, 2025, in connection with the closing of the issuance and sale of the ENvue Medical,, Inc.’s (the “ Company ”) Series H Convertible Preferred Stock, par value $0.001 per share (the “Preferred Stock”) on July 18, 2025, the Company filed a Certificate of Designation of Preferences, Rights and Limitations of the Series H Convertible Preferred Stock with the Secretary of State of…

The filing describes an amendment to the long-term incentive plan for compliance with Israeli tax laws and other minor updates.

Chief Executive Officer — Doron Besser, M.D.: Amended and restated employment agreement with Dr. Doron Besser as CEO.

Director — Christopher Fashek, Thomas Mika, Martin Goldstein, Brian Murphy: Multiple directors retired from the board for personal reasons.

Entry into a Material Definitive Agreement. On September 16, 2025, NanoVibronix, Inc. (the “ Company ”) entered into a securities purchase agreement (the “Purchase Agreement”) with a single institutional investor, pursuant to which the Company agreed to issue and sell (i) 74,114 shares (the “ Shares ”) of the Company’s common stock, $0.001 par value per share (the “ Common Stock ”), and (ii) prefunded warrants (the “ Prefunded Warrants ”) to purchase up to 217,090 shares of Common Stock (the…

Changes in Registrant’s Certifying Accountant. (a) Dismissal of Independent Registered Public Accounting Firm On August 12, 2025, the Audit Committee of the Board of Directors (the “ Committee ”) of NanoVibronix, Inc. (the “ Company ”) approved the dismissal of Zwick CPA PLLC (“ Zwick ”) as the Company’s independent registered public accounting firm, effective as of the same date. The reports of Zwick on the Company’s consolidated financial statements for the two most recent fiscal years, end…

Chief Financial Officer — Stephen Brown: The CFO's employment agreement was amended and restated, with no indication of a departure or significant change in role.

Material Modification to Rights of Security Holders. To the extent required by

Executive Vice President of Finance and Chief Accounting Officer, Corporate Secretary — Rita Silberberg: Ms. Silberberg was appointed to multiple senior roles within the company.

Material Modification to Rights of Security Holders. The matters described in

Unregistered Sales of Equity Securities The matters described in

Entry into a Material Definitive Agreement. Securities Purchase Agreement On July 18, 2025, NanoVibronix, Inc. (the “ Company ”) entered into a Securities Purchase Agreement (the “ Purchase Agreement ”) with a certain institutional investor (the “ Investor ”), pursuant to which it agreed to sell to the Investors (i) an aggregate of 8,889 shares of the Company’s newly-designated Series H Convertible Preferred Stock, with a par value of $0.001 per share and a stated value of $1,000 per share (t…

Creation of a Direct Financial Obligation or an Obligation under an Off Balance Sheet Arrangement of a Registrant The matters described in

Other Events. On July 11, 2025, NanoVibronix, Inc. (the “ Company ”) opened and adjourned its Special Meeting of Stockholders (the “ Special Meeting ”) due to an absence of a quorum in accordance with the Company’s Amended and Restated Bylaws, as amended, without any business being conducted. The Special Meeting will be reconvened virtually with respect to all proposals at 10:00 a.m. Eastern Time on Thursday, July 17, 2025 (the “ Reconvened Special Meeting ”), at www.virtualshareholdermeeting…

Material Modification to Rights of Security Holders To the extent required by

Chief Executive Officer (CEO) — Doron Besser, M.D.: Dr. Doron Besser was promoted to CEO and Brian Murphy retired from the position.

Material Modification to Rights of Security Holders. The matters described in

Entry into a Material Definitive Agreement. Underwritten Public Offering On May 14, 2025, NanoVibronix, Inc. (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) by and between the Company and Dawson James Securities, Inc. as representative of the underwriters named on Schedule I of the Underwriting Agreement (the “ Representative ”), pursuant to which the Company agreed to issue in a firm commitment underwritten offering (the “ Offering ”) (i) 400,000 sha…

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth in

Entry into a Material Definitive Agreement. Promissory Note On April 11, 2025, ENvue Medical Holdings, Corp. (“ ENvue ”), a wholly-owned subsidiary of NanoVibronix, Inc. (the “ Company ”), issued a promissory note (the “ Note ”) to Alpha Capital Anstalt (the “ Lender ”) in the principal amount of $360,000 (the “ Principal Amount ”), together with all accrued interest thereon. The Note has a maturity date of June 11, 2025 (the “ Maturity Date ”) and on the Maturity Date, the aggregate unpaid P…